http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010043582-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f02b627b28e4946aa2340c0125e151a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a53b927360c6ae72fea63ac79cba8cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f98e77d1aba3a9c2fb565cc42cc7c76f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bee94bd19ccbba70428e5d72bab8df15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_312d72c5a58b1ea23105467d4a4f84fd
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
filingDate 2009-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce672febebe0e78e9d4c6eff27f38dc4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ddf8c3336c25094a3d83055fcbf2f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b52e73c50bfb16357a8ee3bb19890e2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71886853ae6f7ad593fa0490ff36f8a6
publicationDate 2010-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2010043582-A1
titleOfInvention Method for the treatment of cancer
abstract The present invention relates to combination therapies for the treatment of cancer using LNA oligomers targeting Bcl-2 in conjunction with CD-20 inhibitors, such as Rituximab, or a CD20 antibody is selected from the group consisting of Ofatumumab (2F2), 11B8, 7D8, 2C6, Veltuzumab, AME-133v Ibritumomab Tiuxetan, Tositumomab, TRU-015, 2H7.vl6, Ocrelizumab, Pro131921, R7159, and GA-101.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020014139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112384219-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7352582-B2
priorityDate 2008-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004056971-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005061710-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009049841-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9877416
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID244300720
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415574
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226581976
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414876
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248183136
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1134
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3672
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399239
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243828357
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22633866
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226520164
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87072439
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226520163
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245816266
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87072441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395293
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87072440
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226520165
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245054859
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409524
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402925
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8182
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7708
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID243624910
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5789
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12529
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65075
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393519
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248800696
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22873106
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247172237
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226403891
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413814
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415044
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413813
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID519973
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21868329
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15793
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID131813
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID221493
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87081022
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414409
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129262772
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID102548

Total number of triples: 84.